Rational use of antimicrobials in obstetric practice in view of growing antibiotic resistance

Background. Urogenital infections are a leading risk factor for isthmic-cervical insufficiency and preterm labor, and the main role in most cases is played by representatives of opportunistic microflora. The most frequent forms of genital infections are bacterial vaginosis, vulvovaginal candidiasis and urogenital trichomoniasis. Bacterial vaginosis is essentially a manifestation of vaginal dysbiosis, it is not lifethreatening, but it is a risk factor for serious complications among pregnant women, namely, it increases the risk of spontaneous abortion, premature labor, premature rupture of fetal membranes, low birth weight and is a co-factor of persistent genital infections. Given the impact of infectious diseases on the course and outcome of pregnancy, as well as the limited possibilities of therapy during pregnancy, it is important to conduct pregravidarial preparation, including screening of infectious diseases, but over 40% of pregnancies are unplanned, which significantly increases the risks of complications of pregnancy and labor, intrauterine infection of the fetus and newborn.

Conclusion. Infectious and inflammatory diseases are an important problem of modern obstetrics and gynecology, especially of rational antimicrobial therapy in conditions of the widespread pathogens’ resistance. The local application of vaginal suppositories Limenda is effective for vulvovaginal treatment in such cases. Furthermore, systemic antibacterial therapy is necessary, spiramycin is very useful in case jozamicin`s withdrawal from the market by Russian Ministry of Health (No. 25-6/159 dated 03/14/24). Macrolide Doramitcin WM is applicable from the first trimester of pregnancy and allows equivalent replacement of the departed 16-membered macrolide.

1. Nikonov A. P., Astsaturova O. R. Infections in obstetrics and gynecology. Diagnosis and antimicrobial therapy. М., 2014. 46 p. (In Russ.)

2. Clinical recommendations for the diagnosis and treatment of diseases accompanied by pathologic discharge from the female genital tract. Moscow, 2019. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. (In Russ.) URL: https://library.mededtech.ru/rest/documents/Rek/.

3. Witkin S. S. The vaginal microbiome, vaginal antimicrobial defense mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG. 2015; 122 (2): 213-218.

4. Preterm labor: clinical recommendations, 2020. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. (In Russ.) URL: https://www.cr/vinzdrav.gov.ru.

5. Istmic-cervical insufficiency: clinical recommendations, 2020. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. (In Russ.) URL: https://www.cr/vinzdrav.gov.ru.

6. Sangkomkamhang U. S., Lumbiganon P., Prasertcharoensuk W., Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. 2015; (2): CD006178.

7. Thinkhamrop J., Hofmeyr G. J., Adetoro O., Lumbiganon P., Ota E. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev. 2015; (6): CD002250.

8. Product label of Limenda, LLC "WORLD MEDICINE", Russia. (In Russ.)

9. Ilina I. Yu., Dobrokhotova Yu. E. Bacterial vaginosis. Possible solutions to the problem. RMZh. 2020; 11: 76-78. (In Russ.)

10. Normal pregnancy: clinical recommendations, 2023. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. (In Russ.) URL: https://www.cr/vinzdrav.gov.ru.

11. Bitsadze V. O., Radetskaya L. S. Experience of using the local combination product containing miconazole and metronidazole for the treatment of bacterial vaginosis and vulvovaginal candidiasis in pregnant women. Ginekologiya. 2016; 18 (6): 56-60. (In Russ.)

12. Kükner S., Ergin T., Ciçek N., et al. Treatment of vaginitis. Int J Gynaecol Obstet. 1996; 52 (1): 43-47. DOI: 10.1016/0020-7292(95)02531-6.

13. Savchenko T. N., Khashukoeva A. Z., Ilyina I. Y., Agaeva M. I., Narimanova M. R., Dergacheva I. A. Inflammatory diseases of organs: influence on reproductive state of women, prospects of the treatment. Lechaschi Vrach. 2014; 12: 8. (In Russ.)

14. Khashukoeva A. Z., Agaeva M. I., Agaeva Z. A., Burdenko M. В. Inflammatory diseases of pelvic organs: algorithm of diagnostics and treatment. Akusherstvo i ginekologiya. Prilozhenie. 2024; 13: 4-6. (In Russ.)

15. Instructions for medical use of the drug Doramitcin WM LLC "WORLD MEDICINE" Russia. (In Russ.)

16. Lobzin Yu. V., Vasiliev V. V., Timchenko V. N., Vasilieva I. S. Toxoplasmosis of pregnant women: achievements and unresolved issues. RMZh. 2001; 37-39. (In Russ.)

17. Peyron F., Wallon M., Liou C., Garner P. Treatments for toxoplasmosis in pregnancy (Cochrane Review). In The Cochrane Library 2003; Oxford: Update Software.

18. Kuzmin V. N. New opportunities in the treatment of mixed bacterial infections in women. Lechaschi Vrach. 2022; 11 (25). (In Russ.)

19. Stepanova E. F., Remezova I. P., et al. Biopharmaceutical features of different metronidazole drugs used in gynecologic practice. Lekarstvennye sredstva i ratsionalnaya pharmakoterapiya. 2021; 4. (In Russ.)

20. Dobrokhotova Yu. E., Borovkova E. I., Zalesskaya S. A., et al. Diagnosis and management patients with cervical insufficiency. Ginekologiya. 2018; 20 (2): 41-45. (In Russ.)